Continuous treatment strategies improve psychological status and quality of life in patients with atopic dermatitis

Table 3 Quality of life outcomes, mean ± SD

Indicator	Intervention group (n = 60)	Control group (n = 60)	P value
Mean DLQI score at baseline	16.8 ± 3.9	16.5 ± 3.8	0.76
Mean DLQI score at 12 months	5.2 ± 2.1	9.6 ± 2.8	< 0.001
Reduction in DLQI score	11.6 ± 3.2	6.9 ± 2.9	< 0.001
Percentage of patients with DLQI ≤ 5 at 12 months (%)	75	45	< 0.001
Additional indicators
SF-36 PCS	80 ± 10	70 ± 12	< 0.05
SF-36 MCS	82 ± 11	72 ± 13	< 0.05
EQ-5D health state score	0.85 ± 0.10	0.75 ± 0.12	< 0.05
Pain interference score (0-10 scale)	2.0 ± 1.0	4.0 ± 1.5	< 0.001

DLQI: Dermatology life quality index; PCS: Physical component score; MCS: Mental component score; SF-36: Short form-36 health survey; EQ-5D: EuroQol 5-dimension.